Navigation Links
Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
Date:3/26/2013

n>; Istanbul-based SAVAS Medikal Inc. to cover hospitals in Turkey; and Netherlands-based EMELCA Bioscience, covering hospitals in the Benelux countries.  Pursuant to these agreements, strategic market development activities have commenced those regions and Venaxis anticipates announcing additional agreements in the near term that cover the additional targeted EU territories.

The Company also strengthened its balance sheet with an underwritten public offering in late 2012, for which Venaxis received approximately $4.7 million in total gross proceeds, including full exercise of the underwriter's over-allotment option.  The Company ended the year with $12.1 million in cash, cash equivalents and short-term investments, which Venaxis believes is sufficient to complete the ongoing U.S. pivotal trial, as well as advance the market development activities in Europe.

Mr. Lundy concluded, "We have emerged successfully from 2012 as a pure-play in vitro diagnostics company with sufficient capital to advance our new and innovative diagnostic product that we believe fulfills an important need in the emergency care market.  As study enrollment continues to ramp in the U.S. and we continue to gain traction and gather market intelligence in Europe, we look forward to providing timely updates on our key achievements."

Conference Call Information
The Company has scheduled its quarterly conference call and webcast for today, March 26, 2013, at 4:30 p.m. ET.  Interested participants and investors may access the conference call by dialing 1-800-860-2442 (U.S.), 1-866-605-3852 (Canada) or 1-412-858-4600 (international).  A live audio webcast will be accessible via the Investor Relations section of the Venaxis web site, ir.venaxis.com. 
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AspenBio Pharma Changes Company Name to Venaxis, Inc.
2. Venaxis to Present at 2013 BIO CEO and Investor Conference
3. Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
4. Venaxis to Present at 25th Annual ROTH Conference
5. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
6. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
7. Medical Imaging Information Systems Market to 2017 - Replacement of Legacy Systems and Advances in Software Present Growth Opportunities
8. Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China
9. URAC sets standards for community pharmacy, advances dialogue about pharmacists as medication experts
10. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
11. Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Restore Health, a leading personalized ... announced that it is now offering pharmacogenetics testing ... individual based upon their particular genetic makeup. Comprehensive ... interaction between a patient,s genetics and their entire ... to provide this new service to healthcare providers ...
(Date:7/24/2014)... 24, 2014  Mettler-Toledo International Inc. (NYSE: ... Provided below are the highlights: , Sales ... compared with the prior year. Reported sales increased 5% ... Net earnings per diluted share as reported (EPS) were ... 2013. Adjusted EPS was $2.57, an increase of 9% ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... (Nasdaq: BIOD ) today reported financial results for the ... Year 2011 Financial Results Biodel reported a net loss ... or $0.20 per share, compared to a net loss of $11.1 ... prior year. Research and development expenses were $5.5 ...
... CFN ), a leading, global medical technology company, ... Dec. 31, 2010. "Our strong second quarter results ... Infection Prevention businesses, and a benefit from a lower tax ... had announced in November 2010 his plans to retire. On ...
Cached Medicine Technology:Biodel Reports First Quarter Fiscal Year 2011 Financial Results 2Biodel Reports First Quarter Fiscal Year 2011 Financial Results 3Biodel Reports First Quarter Fiscal Year 2011 Financial Results 4Biodel Reports First Quarter Fiscal Year 2011 Financial Results 5Biodel Reports First Quarter Fiscal Year 2011 Financial Results 6CareFusion Reports Second Quarter Fiscal 2011 Results 2CareFusion Reports Second Quarter Fiscal 2011 Results 3CareFusion Reports Second Quarter Fiscal 2011 Results 4CareFusion Reports Second Quarter Fiscal 2011 Results 5CareFusion Reports Second Quarter Fiscal 2011 Results 6CareFusion Reports Second Quarter Fiscal 2011 Results 7CareFusion Reports Second Quarter Fiscal 2011 Results 8CareFusion Reports Second Quarter Fiscal 2011 Results 9CareFusion Reports Second Quarter Fiscal 2011 Results 10CareFusion Reports Second Quarter Fiscal 2011 Results 11CareFusion Reports Second Quarter Fiscal 2011 Results 12CareFusion Reports Second Quarter Fiscal 2011 Results 13CareFusion Reports Second Quarter Fiscal 2011 Results 14CareFusion Reports Second Quarter Fiscal 2011 Results 15
(Date:7/25/2014)... The report, "Wireless Gigabit (WiGig) Market ... Alliance, Access Points, Routers, Residential Gateways, Backhaul Equipment) ... Analysis (2014 - 2019)," provides a comprehensive market ... by WiGig enabled products, and regions. The report ... WiGig market, and provides the quantitative (market size ...
(Date:7/25/2014)... 2014 Garth Brooks Chicago tickets go ... Arena in Rosemont. Garth Brooks was one of the leaders ... first single in 1989. Since "Much Too Young (To Feel This ... from the Tulsa, Okl. native and in the years that he ... back on a stage and in the recording studio. Between 2001 ...
(Date:7/25/2014)... -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... Patent Pool (MPP) and Gilead Sciences, Inc. to ... promising new HIV medication. The agreement was announced ... in Melbourne, Australia. , While TAF is ... suggests it could be a key ingredient in ...
(Date:7/25/2014)... New York, New York (PRWEB) July 25, 2014 ... reviews JDRF’s revenue and spending during fiscal year 2013 (July ... government’s National Institutes of Health (NIH), the JDRF is the ... world. It has global reach and relationships with most ... better positioned to deliver a cure for type 1 diabetes ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Project Ninety ... episode of Innovations with Ed Begley Jr, airing later ... times TBA. , For more than four decades, Project ... Area community through its residential alcohol and substance abuse ... on Project Ninety's humble idea and how it has ...
Breaking Medicine News(10 mins):Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Wireless Gigabit (WiGig) Market Projected to $10.53 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3
... ... a leading provider of information-based technology services to the health care industry, ... Texas in addition to its services that are provided to physicians throughout ... New Hampshire and is owned by Medical Protective, part of the Berkshire ...
... NJ A recent study published in International ... extract from the bark of the French maritime pine ... associated with various health problems. Dr. Raffaella Canali ... in Rome, Italy, found that Pycnogenol inhibits the generation ...
... , , PORTLAND, Ore., ... reform is the power of simple questions that people can ask each ... , To spark this effort, Regence BlueCross ... to inspire debate, discussion, and ultimately engagement and action by consumers. As ...
... , , CARY, N.C., ... CRTX ), a specialty pharmaceutical company focused on acquiring, ... and related markets, today announced that it has submitted ... Administration (FDA) for an extended-release antitussive product (CRTX 067) ...
... HARRISBURG, Pa., July 15 The Department of Environmental Protection and ... day for June 16 in the Philadelphia region. , ... will be code ORANGE for ozone in the region, which includes ... , The U.S. Environmental Protection Agency,s standardized ...
... , PITTSBURGH, Jul. 15 Leo W. Gerard, President ... to the U.S. House of Representatives, health care reform bill. , ... ) , , ... of efforts by the U.S. House leadership to fix our broken ...
Cached Medicine News:Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 2Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 3Health News:Study demonstrates the anti-inflammatory properties of pine bark extract 2Health News:Regence Launches Effort to Further Health Care Debate 2Health News:Regence Launches Effort to Further Health Care Debate 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Air Quality Action Day Forecast for July 16 in Philadelphia Region 2Health News:Statement by USW President Leo W. Gerard on U.S. House Health Care Reform Bill 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: